Theravance Biopharma
901 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.theravance.com/
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
248 articles about Theravance Biopharma
-
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
6/25/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced that the first COVID-19 patient has been dosed in a Phase 2 study of TD-0903.
-
Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
5/6/2020
TD-0903, an investigational lung-selective nebulized Janus kinase inhibitor (JAKi) with the potential to treat Acute Lung Injury in hospitalized patients with COVID-19, has progressed to Phase 1 clinical testing
-
Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020
4/28/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its first quarter 2020 financial results and provide a business update after market close on Wednesday, May 6, 2020.
-
Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
4/23/2020
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that the first healthy volunteer has been dosed in a Phase 1 study
-
Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis
4/20/2020
Manuscript Provides Comprehensive Summary of Positive Results from Clinical and Preclinical TD-1473 Studies Conducted to Date
-
Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury
4/9/2020
- Clinical Trial Application (CTA) submitted in the United Kingdom for first in human study of TD-0903, an investigational lung-selective nebulized JAKi with potential to treat Acute Lung Injury caused by COVID-19 - Near-term clinical development program enables progression from healthy volunteers to hospitalized COVID-19 patients
-
Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes
3/2/2020
Theravance Biopharma, Inc. (NASDAQ: TBPH)today announced the closing of a private placement of $400 million of non-recourse Triple II 9.5% fixed rate term notes.
-
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
2/24/2020
- YUPELRI® (revefenacin) is realizing strong customer acceptance and market uptake, in partnership with Mylan - Phase 1 of TD-5202 single-ascending dose and multiple-ascending dose studies evaluated the safety and tolerability of TD-5202 in healthy subjects; data showed TD-5202 was generally well tolerated, supporting advancement - Full-year operating loss, excluding share-based compensation expense, was lower than the Company's previously stated financial guidance for 2019 [
-
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
2/18/2020
Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations
-
Theravance Biopharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
2/13/2020
Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2019 financial and operating results and provide a business update after market close on Monday, February 24, 2020
-
Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
2/12/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced the pricing of its underwritten public offering of 5,500,000 ordinary shares at a price to the public of $27.00 per share.
-
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares
2/10/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced that it intends to offer $150.0 million of ordinary shares in an underwritten public offering.
-
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
-
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
1/7/2020
Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast its presentation at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020.
-
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
12/23/2019
Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today announced that the companies have entered into a global license agreement for Theravance Biopharma's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.
-
Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.
-
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
12/3/2019
Novel Organ-Selective Pan-JAK Inhibitor Specifically Designed to Target Airway Inflammation in the Lung With Minimal Systemic Exposure Allergen Challenge Study Expected to Provide Key Insights to Support Ongoing Clinical Development of TD-8236
-
While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
-
Theravance Biopharma to Present at Two Upcoming Investor Conferences
11/26/2019
A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com
-
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.